BioWorld

Dec. 13, 2010

The Game of Risk: Mitigation, Funding, World Domination

The object of the military-themed board game might be total world domination, but in the biotech game of risk, just surviving can be tricky enough. Read More

Money Raised Year to Date

MMRC ASH Data Validate Better-Faster-Cheaper Trials

Cancer Drug Causes Cancer: Catastrophe or Minor Blip?

Money Raised By Biotech in 2010

Week in Review

Word on the Street

Week in Washington

Phase I Clinical Trials Update: November 2010

Phase II Clinical Trials Update: November 2010

Phase III Clinical Trials Update: November 2010

American Association for the Study of Liver Diseases

American College of Rheumatology

American Heart Association

European Organisation for Research and Treatment of Cancer

Non-U.S. Clinical Trials & Regulatory Actions: Nov. 2010

FDA Submissions, Approvals & Other Actions: Nov. 2010

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2024.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for December 17, 2024.

Second insulin receptor offers new therapeutic avenues

BioWorld Science

Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...

Mechanism underlying so-called idiopathic autism inception unveiled

BioWorld Science

Investigators at the Institute for Research in Biomedicine (IRB Barcelona) have unraveled how and why the absence of a neuronal microexon in cytoplasmic...

Drug duo to Repare lack in gyno cancers? Phase I shows promise

BioWorld

Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...